Loading stock data…
Larimar Therapeutics (LRMR)
$3.20-0.46 (-12.57%)
Market ClosedLast close Jun 29
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Larimar Therapeutics, Inc. in the Healthcare sector is trading at $3.20 with a market capitalization of $360M. Wall Street consensus targets $15.11 (9 analysts), implying a +372.2% move over the next 12 months. The stock is currently near its 52-week low of $2.71, remaining 19.6% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +372.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$31.12M↑ | -$64.02M↓ | -$49.50M↓ | -$27.79M↑ | -$31.19M |
| Net Income | -$29.61M↑ | -$62.50M↓ | -$47.71M↓ | -$26.18M↑ | -$29.28M |
Peer Comparison
JNJUNHPFE
Fundamentals
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clini...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$360.47M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-105.04%
Volume
Today's trading volume
13.40M
Recent News
Larimar Therapeutics Shares Drop Following Clinical Update and Regulatory Filing (LRMR)
Larimar Therapeutics (NASDAQ:LRMR) shares declined 17% on Monday after the company released new data from its ongoing open-label study and confirmed the submission of the first section of its rolling Biologics License Application (BLA) seeking accelerated approval for nomlabofusp as a treatment for Friedreich’s ataxia. The biotechnology company said the initial BLA module has been submitted to the U.
Larimar's Rare Disease Push Just Hit A Key Inflection Point — What Investors Need To Know
Larimar submitted the module of a rolling biologics license application to the U.S. Food and Drug Administration for the accelerated approval of nomlabofusp for Friedreich’s ataxia.
Larimar Therapeutics Files First Module of BLA With US FDA for Nomlabofusp
Larimar Therapeutics (LRMR) said Monday that it has filed the first module of its rolling Biologics
Exploring 3 High Growth Tech Stocks in US Market
The United States market remained flat over the last week but has shown a strong performance with a 24% increase over the past year, and earnings are forecast to grow by 19% annually. In this context, identifying high growth tech stocks involves looking for companies that not only align with these optimistic earnings forecasts but also demonstrate robust innovation and adaptability in an ever-evolving industry landscape.
Exploring US High Growth Tech Stocks This May 2026
Over the last 7 days, the United States market has risen by 1.1% and is up 27% over the past year, with earnings forecasted to grow by 17% annually. In this favorable environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to leverage these promising conditions.